Revolution Medicines Inc. (RVMD), a late-stage clinical oncology company, announced today positive topline data from the Phase 3 RASolute trial for Daraxonrasib, noting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (PCAD) who were administered the drug.
Daraxonrasib is an investigational, oral RAS (ON) multi-selective, non-covalent inhibitor that targets RAS mutations in PCAD tumors. The drug was granted an Orphan drug and Breakthrough therapy designation by the U.S. Food and Drug Administration (FDA).
The Phase 3 RASolute 302 clinical trial is an ongoing global, randomized, registrational study to establish the efficacy and safety of daraxonrasib. Patients of PDAC enrolled were administered up to 300 mg of daraxonrasib daily with an investigator's choice of cytotoxic chemotherapy. Primary endpoints of PFS and OS were found to be improved by statistically significant and clinically meaningful margins.
Additionally, daraxonrasib is being investigated in the treatment of non-small cell lung cancers (NSCLCs), and colorectal cancers.
RVMD closed Friday at $96.43, up 0.22%. In the premarket, shares are trading at $129.64, up 34.44%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.